☆ 4.7 Article

Discovery and Optimization of Neutralizing SARS-CoV-2 Antibodies Using ALTHEA Gold Plus Libraries™

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants

Qian Wang et al.

Summary: The BQ and XBB subvariants of SARS-CoV-2 Omicron, with additional spike mutations, are rapidly expanding and have altered antibody evasion properties. Neutralization of BQ.1, BQ.1.1, XBB, and XBB.1 by vaccinated individuals and infected persons' sera was significantly impaired, including those boosted with a WA1/BA.5 bivalent mRNA vaccine. The titers against BQ and XBB subvariants were much lower than observed before, indicating that these subvariants pose a serious threat to current COVID-19 vaccines and render all authorized antibodies inactive.

CELL (2023)

Add to Collection

Article Multidisciplinary Sciences

A pandemic-enabled comparison of discovery platforms demonstrates a nai''ve antibody library can match the best immune-sourced antibodies

Fortunato Ferrara et al.

Summary: This study demonstrates that highly potent human neutralizing antibodies against the SARS-CoV-2 spike protein can be generated directly from a semisynthetic naive antibody library. These antibodies have comparable affinities, developability properties, and neutralization activities to those from immune sources, providing a potential alternative to traditional immunization methods.

NATURE COMMUNICATIONS (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

Antibodies to combat viral infections: development strategies and progress

Giuseppe Pantaleo et al.

Summary: Monoclonal antibodies are attractive as potential therapeutics and prophylactics for viral infections due to their high specificity and ability to enhance immune responses. Advances in antibody engineering and structural biology have led to the development of monoclonal antibodies targeting various viruses, and have implications for vaccine design.

NATURE REVIEWS DRUG DISCOVERY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies

Juan C. Almagro et al.

Summary: This review examines the characteristics of nine therapeutic antibodies approved for Emergency Use Authorization in response to the COVID-19 pandemic. It highlights the neutralization profile against variants of concern (VOCs), selection methods, somatic mutations, isotype, Fc modifications, and epitopes recognized on the receptor-binding domain (RBD) of SARS-CoV-2. The review concludes that effective therapeutic antibodies bind to an epitope formed by conserved residues critical for the RBD:hACE-2 interaction. The information presented here can aid in the design of more efficacious antibodies for the prevention and treatment of COVID-19 and other infectious diseases.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Immunology

In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a Semi-Immune Phage Display Library

Edith Gonzalez-Gonzalez et al.

Summary: Neutralizing antibody IgG-A7 efficiently neutralizes different strains of SARS-CoV-2 and provides protection against infection in transgenic mice. IgG-A7 shows potential as a suitable candidate for antibody-based drugs to treat and prevent SARS-CoV-2 variants of concern (VOCs) infections.

ANTIBODIES (2022)

Add to Collection

Article Immunology

Anti-SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library

Ivette Mendoza-Salazar et al.

Summary: This report describes the discovery and characterization of antibodies with potential broad SARS-CoV-2 neutralization profiles. These antibodies, obtained from a convalescent patient, showed cross-reactivity to different variants of SARS-CoV-2, including the Omicron variant.

ANTIBODIES (2022)

Add to Collection

Article Multidisciplinary Sciences

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein

Cheolmin Kim et al.

Summary: A human monoclonal antibody called CT-P59 has been shown to effectively neutralize SARS-CoV-2 and demonstrate significant therapeutic effects in animal models, making it a promising candidate for COVID-19 treatment.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Microbiology

Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study

Xiaojie Wu et al.

Summary: This study reports the tolerability, safety, pharmacokinetics, and immunogenicity of a recombinant human anti-SARS-CoV-2 monoclonal antibody, etesevimab, in healthy adults, showing good tolerability after a single dose within the range of 2.5mg/kg to 50mg/kg.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Multidisciplinary Sciences

Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain

Timothy J. C. Tan et al.

Summary: This study identified two common IGHV3-53/3-66 RBD antibody clonotypes with distinct sequence motifs in CDR H3 that appear to be related to different light chain pairings. Additionally, the authors demonstrated that the Y58F somatic hypermutation increases the binding affinity of IGHV3-53/3-66 RBD antibodies with a short CDR H3.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Medicine, General & Internal

Development and Evaluation of a Set of Spike and Receptor Binding Domain-Based Enzyme-Linked Immunosorbent Assays for SARS-CoV-2 Serological Testing

Rosa Camacho-Sandoval et al.

Summary: This paper reports the implementation and validation of anti-SARS-CoV-2 IgG serological assays using S1 and RBD proteins coated ELISA plates, showing high sensitivity and specificity. The study validated the assays with RT-PCR positive COVID-19 sera and further confirmed their robustness with a large sample of serum collected at different time points.

DIAGNOSTICS (2021)

Add to Collection

Article Biochemical Research Methods

Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile

Francisco C. Perdomo-Abundez et al.

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2020)

Add to Collection

Article Multidisciplinary Sciences

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Rui Shi et al.

NATURE (2020)

Add to Collection

Article Medicine, Research & Experimental

ALTHEA Gold Libraries™: antibody libraries for therapeutic antibody discovery

Philippe Valadon et al.

MABS (2019)

Add to Collection

Review Immunology

Phage Display Libraries for Antibody Therapeutic Discovery and Development

Juan C. Almagro et al.

ANTIBODIES (2019)

Add to Collection

Article Chemistry, Medicinal

High-throughput melting-temperature analysis of a monoclonal antibody by differential scanning fluorimetry in the presence of surfactants

Tim Menzen et al.

JOURNAL OF PHARMACEUTICAL SCIENCES (2013)

Add to Collection

Article Genetics & Heredity

Divergent human populations show extensive shared IGK rearrangements in peripheral blood B cells

Katherine Jean Louise Jackson et al.

IMMUNOGENETICS (2012)

Add to Collection

Article Biochemistry & Molecular Biology

Human Framework Adaptation of a Mouse Anti-Human IL-13 Antibody

Johan Fransson et al.

JOURNAL OF MOLECULAR BIOLOGY (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.